Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2016 07:45 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Submits New Drug Application for Rexista® (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
October 14, 2016 09:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference

TORONTO, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
October 13, 2016 23:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Third Quarter 2016 Results

TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
October 11, 2016 16:46 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt

TORONTO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
October 07, 2016 18:35 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®

TORONTO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
September 22, 2016 16:05 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Responds to Recent Trading Activity

TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
August 25, 2016 16:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

TORONTO, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
July 13, 2016 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Second Quarter 2016 Results

TORONTO, July 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
July 05, 2016 07:30 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect

TORONTO, July 05, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
June 06, 2016 17:30 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Closes Public Offering for US$5.2 Million

TORONTO, June 06, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of...